Alcohol Addiction – Pipeline Review, H1 2018

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction – Pipeline Review, H1 2018, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 10, 4, 1, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

Adial Pharmaceuticals LLC

Arbor Pharmaceuticals LLC

AstraZeneca Plc

BioCorRx Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Curemark LLC

Eli Lilly and Co

Ethypharm SA

H. Lundbeck AS

Heptares Therapeutics Ltd

Indivior Plc

Johnson & Johnson

Kinnov Therapeutics SAS

Kyorin Pharmaceutical Co Ltd

Lohocla Research Corp

Montisera Ltd

Omeros Corp

Opiant Pharmaceuticals Inc

Pfizer Inc

Silence Therapeutics Plc

SK Biopharmaceuticals Co Ltd

Syntropharma Ltd

Tonix Pharmaceuticals Holding Corp

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alcohol Addiction - Overview

Alcohol Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcohol Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcohol Addiction - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Adial Pharmaceuticals LLC

Arbor Pharmaceuticals LLC

AstraZeneca Plc

BioCorRx Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Curemark LLC

Eli Lilly and Co

Ethypharm SA

H. Lundbeck AS

Heptares Therapeutics Ltd

Indivior Plc

Johnson & Johnson

Kinnov Therapeutics SAS

Kyorin Pharmaceutical Co Ltd

Lohocla Research Corp

Montisera Ltd

Omeros Corp

Opiant Pharmaceuticals Inc

Pfizer Inc

Silence Therapeutics Plc

SK Biopharmaceuticals Co Ltd

Syntropharma Ltd

Tonix Pharmaceuticals Holding Corp

Zynerba Pharmaceuticals Inc

Alcohol Addiction - Drug Profiles

(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(disulfiram + selegiline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-705253 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amitifadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANS-6637 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen placarbil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baclofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-1.3656B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carisbamate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-1212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gabapentin enacarbil ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDTic - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

odelepran hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPNT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05190457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RC-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-10406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLN-226 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Oxytocin Receptor for Alcohol and Drug Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcohol Addiction - Dormant Projects

Alcohol Addiction - Discontinued Products

Alcohol Addiction - Product Development Milestones

Featured News & Press Releases

Jan 05, 2018: BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone

Dec 19, 2017: BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102

Oct 17, 2017: Otsuka Submits a Japan NDA for Nalmefene, a Drug to Reduce Alcohol Consumption in Alcohol-Dependent Patients

Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio

Jul 19, 2017: Opiant Pharmaceuticals Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder

Jul 06, 2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas

May 04, 2017: Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology

Feb 28, 2017: Opiant Pharmaceuticals Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder

Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence

Nov 28, 2016: BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA

Sep 15, 2016: BioCorRx Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product

Sep 03, 2016: Baclofen helps reduce the consumption of alcohol in alcohol - dependent patients

Aug 31, 2016: BioCorRx Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology

Jul 25, 2016: Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder

Jul 20, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Alcohol Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Alcohol Addiction – Pipeline by AbbVie Inc, H1 2018

Alcohol Addiction – Pipeline by Addex Therapeutics Ltd, H1 2018

Alcohol Addiction – Pipeline by Adial Pharmaceuticals LLC, H1 2018

Alcohol Addiction – Pipeline by Arbor Pharmaceuticals LLC, H1 2018

Alcohol Addiction – Pipeline by AstraZeneca Plc, H1 2018

Alcohol Addiction – Pipeline by BioCorRx Inc, H1 2018

Alcohol Addiction – Pipeline by Bionex Pharmaceuticals LLC, H1 2018

Alcohol Addiction – Pipeline by Bioprojet SCR, H1 2018

Alcohol Addiction – Pipeline by Chronos Therapeutics Ltd, H1 2018

Alcohol Addiction – Pipeline by Corcept Therapeutics Inc, H1 2018

Alcohol Addiction – Pipeline by Curemark LLC, H1 2018

Alcohol Addiction – Pipeline by Eli Lilly and Co, H1 2018

Alcohol Addiction – Pipeline by Ethypharm SA, H1 2018

Alcohol Addiction – Pipeline by H. Lundbeck AS, H1 2018

Alcohol Addiction – Pipeline by Heptares Therapeutics Ltd, H1 2018

Alcohol Addiction – Pipeline by Indivior Plc, H1 2018

Alcohol Addiction – Pipeline by Johnson & Johnson, H1 2018

Alcohol Addiction – Pipeline by Kinnov Therapeutics SAS, H1 2018

Alcohol Addiction – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Alcohol Addiction – Pipeline by Lohocla Research Corp, H1 2018

Alcohol Addiction – Pipeline by Montisera Ltd, H1 2018

Alcohol Addiction – Pipeline by Omeros Corp, H1 2018

Alcohol Addiction – Pipeline by Opiant Pharmaceuticals Inc, H1 2018

Alcohol Addiction – Pipeline by Pfizer Inc, H1 2018

Alcohol Addiction – Pipeline by Silence Therapeutics Plc, H1 2018

Alcohol Addiction – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018

Alcohol Addiction – Pipeline by Syntropharma Ltd, H1 2018

Alcohol Addiction – Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018

Alcohol Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H1 2018

Alcohol Addiction – Dormant Projects, H1 2018

Alcohol Addiction – Dormant Projects, H1 2018 (Contd..1), H1 2018

Alcohol Addiction – Dormant Projects, H1 2018 (Contd..2), H1 2018

Alcohol Addiction – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Alcohol Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports